Article

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

2021-10-21

Abstract excerpt

<h4>ABSTRACT</h4> Lung cancer is the leading cause of cancer death worldwide, with lung adenocarcinoma being the most common subtype. Many oncogenes and tumor suppressor genes are altered in this cancer type and the discovery of oncogene mutations has led to the development of targeted therapies that have improved clinical outcomes. However, a large fraction of lung adenocarcinomas lacks mutations in known oncoge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d288c083-2ca6-58ee-9979-2a9bf7224687
DOI: 10.1101/2021.10.20.464849

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilitiesDOI 10.1101/2021.10.20.464849Read

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.Semantic proximity Read

A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung CancerSemantic proximity Read

Mouse models of human non-small-cell lung cancer: raising the bar.Semantic proximity Read

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung AdenocarcinomaSemantic proximity Read

Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.Semantic proximity Read

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.Semantic proximity Read

A multiplexed in vivo approach to identify driver genes in small cell lung cancerSemantic proximity Read

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.Semantic proximity Read

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Semantic proximity Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read